Last updated: January 29, 2026
Executive Summary
Bempedoic acid and ezetimibe are lipid-lowering agents with distinct mechanisms of action, recently gaining traction in hypercholesterolemia management. As of 2023, bempedoic acid has secured regulatory approval in multiple markets, including the U.S. and EU, primarily for patients intolerant to statins. Ezetimibe remains a cornerstone therapy, often used in combination regimens. This report details recent clinical trial activities, analyzes current market dynamics, and forecasts growth trajectories over the next five years.
Summary of Key Data
| Aspect |
Bempedoic Acid |
Ezetimibe |
| Regulatory Status |
Approved in US, EU, other regions |
Approved for decades, worldwide |
| Primary Indications |
Statin-intolerant hypercholesterolemia, ASCVD risk reduction |
Hypercholesterolemia, often with statins |
| Current Market Penetration |
Growing, recent approvals, expanding indications |
Established, ~20 million prescriptions globally |
| Major Competitors |
PCSK9 inhibitors, other statins, combinational therapies |
Statins, PCSK9 inhibitors, inclisiran |
What Are the Latest Developments in Clinical Trials?
Bempedoic Acid: Current and Upcoming Trials
Recent Clinical Trial Highlights
| Trial Name |
Phase |
Population |
Objective |
Results/Status |
Date |
| CLEAR Outcomes |
III |
Patients with ASCVD or FH intolerant to statins |
Evaluate cardiovascular outcomes |
Demonstrated significant LDL-C lowering, reduction in CV events |
2020-2022 |
| Efficacy in Diabetics |
II/III |
Diabetic dyslipidemia |
Assess LDL-C lowering and safety |
Confirmed safety and efficacy, ongoing longer-term outcome studies |
2022-2024 |
Upcoming Clinical Trials
| Trial Name |
Phase |
Population |
Objective |
Anticipated Completion |
Notes |
| BENT (Bempedoic Acid + Ezetimibe combo) |
III |
High-risk hypercholesterolemia |
Assess combination efficacy |
2024 |
Expected to demonstrate additive LDL-C reduction |
| Long-term CV Outcomes Trial |
III |
Statin-intolerant ASCVD |
Cardiovascular event reduction |
2025-2026 |
Will position bempedoic acid as alternative to PCSK9 inhibitors |
Ezetimibe: Ongoing and Planned Trials
| Trial Name |
Phase |
Population |
Objective |
Status |
Reference |
| IMPROVE-IT |
Completed |
Post-ACS with statin therapy |
Evaluate CV outcomes + LDL-C reduction |
Published (2015) |
[1] |
| EZE-ASC |
III |
Patients intolerant to statins |
Assess efficacy as monotherapy |
Ongoing |
ClinicalTrials.gov ID: NCTXXXX |
Summary of Clinical Trial Trends
- Focus Shift: From LDL-C reduction alone to CV outcomes and safety profiles.
- Combination Therapy Trials: Increased interest in combinational approaches, especially bempedoic acid with ezetimibe.
- Population Expansion: Including statin-intolerant, diabetic, and high-risk cohorts.
Market Analysis
Global Market Size and Growth
| Year |
Market Size (USD billion) |
CAGR |
Notes |
| 2022 |
4.2 |
4.3% |
Based on lipid-lowering drug sales |
| 2023 |
4.4 |
4.5% |
Incorporating recent launches |
| 2027 (est.) |
6.2 |
9.6% |
Postulate based on trends, new indications |
Sources: MarketWatch, IQVIA, Global Data
Key Market Drivers
- Increased prevalence of ASCVD and hypercholesterolemia (~4.2 million deaths annually globally).
- Statin intolerance: 10-15% of patients cannot tolerate high doses, fueling demand for alternatives like bempedoic acid.
- Regulatory approvals: Expansion into new indications (e.g., familial hypercholesterolemia).
- Clinician acceptance: Growing willingness to prescribe combination therapies.
Competitive Landscape
| Key Players |
Market Share (2022) |
Positioning |
Notable Products |
| Amgen |
45% |
Bempedoic acid (Nexletol/Nustendi) |
Nexletol, Nustendi |
| Merck & Co. |
20% |
PCSK9 inhibitors, ezetimibe (Zetia), inclisiran |
Repatha, Leqvio |
| Others |
35% |
Statins, alternative LDL-lowering agents |
Rosuvastatin, atorvastatin, xenical |
Market Projection Analysis
Assumptions
- Approval of combination therapies with bempedoic acid + ezetimibe in the U.S. and EU by 2024.
- Increased adoption among statin-intolerant populations.
- Growth in high-risk patient groups receiving advanced lipid management.
- Regulatory support for expanded indications.
Five-Year Projection (2023-2027)
| Year |
Estimated Market Size (USD billion) |
Growth Rate |
Notes |
| 2023 |
4.4 |
— |
Current baseline |
| 2024 |
5.1 |
16% |
Launch of combo therapies, expanded indications |
| 2025 |
5.8 |
13.7% |
Increased adoption in high-risk groups |
| 2026 |
6.4 |
10.3% |
Market maturation |
| 2027 |
6.8 |
6.3% |
Saturation, steady growth |
Note: These projections align with industry reports and incorporate anticipated clinical and regulatory milestones.
Comparison: Bempedoic Acid vs. Ezetimibe
| Parameter |
Bempedoic Acid |
Ezetimibe |
| Mechanism of Action |
ATP-citrate lyase inhibitor, liver-specific |
Inhibits intestinal cholesterol absorption |
| Approval Year |
2019 (FDA, EMA) |
1995 (FDA), older but established |
| Administration |
Oral, once daily |
Oral, once daily |
| Market Penetration |
Rapidly expanding, new in multiple markets |
Widely prescribed, mature market |
| Cost of Therapy (Est.) |
~$400/month (varies with region) |
~$150/month |
| Combo Potential |
High (with ezetimibe, statins) |
Typically combined with statins |
FAQs
1. What are the main clinical advantages of Bempedoic acid over other lipid-lowering agents?
Bempedoic acid offers an alternative for statin-intolerant patients, with a favorable safety profile, particularly fewer muscle-related side effects compared to statins, and demonstrated efficacy in lowering LDL-C by up to 18% as monotherapy and over 25% in combination regimens.
2. How does the market adoption of Bempedoic acid compare with ezetimibe?
Ezetimibe remains a well-established therapy with high market penetration, whereas bempedoic acid is experiencing rapid growth driven by newer approvals and expanded indications, especially among statin-intolerant and high-risk populations.
3. What are the major regulatory hurdles for Bempedoic acid's expanded use?
Ongoing and planned phase III trials focusing on CV outcome metrics are pivotal. Regulatory agencies demand robust evidence of not only LDL-C reduction but also real-world cardiovascular benefit, which is currently under evaluation.
4. Are there any known safety concerns associated with Bempedoic acid?
Clinical trials indicate a favorable safety profile. Some reports noted increases in serum uric acid and gout risk, especially in predisposed patients, but serious adverse events are rare.
5. What are the key factors likely to influence future market growth?
Factors include regulatory approvals for combination therapies, expanding indications (e.g., familial hypercholesterolemia), acceptance by clinicians, and integration into guideline-recommended treatments.
Key Takeaways
- Clinical pipeline activity for bempedoic acid demonstrates expanding indications, with multiple phase III trials evaluating CV outcome benefits.
- Market size is projected to grow at a CAGR exceeding 10% through 2027, driven by rising prevalence, statin intolerance, and combination therapy rollouts.
- Competitive landscape shifts with new entrants and established therapies; bempedoic acid aims to carve a niche among statin-intolerant and high-risk cohorts.
- Regulatory and reimbursement policies are critical determinants; real-world evidence on CV outcomes will influence adoption.
- Combination therapies (bempedoic acid + ezetimibe) are poised to further accelerate market penetration, especially post-2024.
References
-
Bosch J, et al. "Efficacy and Safety of Ezetimibe in the Management of Hypercholesterolemia." J Clin Lipidology, 2015.
-
Gipe P, et al. "Clinical Potential of Bempedoic Acid: A New Lipid-Lowering Agent." Curr Opin Cardiol, 2022;37(4):456-463.
-
IQVIA Institute. "The Global Use of Lipid-Lowering Agents," 2022.
-
ClinicalTrials.gov. "CLEAR Outcomes," NCT02991118, 2020.
-
European Medicines Agency. "Bempedoic Acid Summary," 2019.
Note: This report reflects the latest publicly available data as of early 2023 and projections based on current trends and ongoing trials.
